cancer weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of cancer weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cardiology
Biotech company and university team up to develop therapeutics for unstable plaque
December 14th, 2004
Cancer and cardiovascular biotech company Kereos said that it has extended its research partnership with Washington University in St. Louis to continue ongoing development of unique therapeutics that specifically target unstable plaque. The development project is being funded under a new $7.3 million Biomedical Research Partnership grant awarded to Washington University School of Medicine from the National Heart, Lung and Blood Institute of the National Institutes of Health. "Unstable plaque lining the walls of coronary arteries is the most dangerous form of the artherosclerotic plaques that underlie heart attacks. When they break off, these plaques...
Source: cancer weekly (2004-12-14)
|
